Morgan Stanley Increases Elanco Animal Health (NYSE:ELAN) Price Target to $24.00

Elanco Animal Health (NYSE:ELAN) had its price target upped by investment analysts at Morgan Stanley from $22.00 to $24.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price target would indicate a potential downside of 8.29% from the company’s previous close.

ELAN has been the subject of a number of other research reports. Barclays initiated coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price objective for the company. JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, February 19th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $26.17 on Wednesday. The company has a current ratio of 2.17, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $13.01 billion, a price-to-earnings ratio of -54.52, a price-to-earnings-growth ratio of 3.98 and a beta of 1.87. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $27.72. The business has a 50 day simple moving average of $24.15 and a 200-day simple moving average of $21.69.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jeffrey N. Simmons bought 22,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the transaction, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This represents a 15.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi purchased 4,500 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were bought at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider directly owned 123,082 shares in the company, valued at $2,625,339.06. This represents a 3.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC raised its holdings in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares in the last quarter. SJS Investment Consulting Inc. increased its position in shares of Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares during the period. Root Financial Partners LLC increased its position in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health in the 4th quarter worth $41,000. Finally, Huntington National Bank lifted its holdings in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the period. 97.48% of the stock is currently owned by institutional investors.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 earnings beat and upbeat outlook: Elanco reported stronger-than-expected Q4 revenue and an EPS beat, gave Q1 and FY 2026 EPS guidance, and the stock hit a new 12‑month high on the reaction. This is the primary fundamental driver of the recent rally. Elanco Animal Health Inc (ELAN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst …
• Positive Sentiment: Analyst bullishness: Multiple firms raised targets — KeyCorp boosted its PT to $29 (overweight) and Leerink raised its PT to $30 — reinforcing upside expectations and supporting investor sentiment. ‘Elanco Animal Health (ELAN) set up well for beats and raises’; PT Raised to $29 at KeyBanc Leerink Partners Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $30.00
• Positive Sentiment: Short interest fell materially in February (down ~20.7%), reducing a source of selling pressure and lowering the potential for short-driven downside. (Data summarized in filings/market reports.)
• Positive Sentiment: High-profile media coverage: Jim Cramer highlighted Elanco’s “comeback story” and CEO Jeff Simmons appeared in an interview, increasing retail/institutional visibility and demand. Jim Cramer Highlights Elanco’s “Comeback Story” Elanco Animal Health CEO Jeff Simmons goes one-on-one with Jim Cramer
• Neutral Sentiment: Investor presentation: Elanco presented at the BofA Securities Animal Health Summit (transcript available) — useful for modelers but less immediately market-moving than earnings and PT changes. Elanco Animal Health Incorporated (ELAN) Presents at BofA Securities Animal Health Summit Transcript
• Neutral Sentiment: Strategic collaboration in Japan: Amlan International and Elanco are running calf‑health educational seminars in Japan — a positive commercial/branding initiative but unlikely to move near‑term results materially. Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health
• Negative Sentiment: More conservative shop: Morgan Stanley raised its price target modestly to $24 but kept an “equal weight” rating — that PT sits below recent market price and signals at least one analyst sees limited near‑term upside. Morgan Stanley Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.